Deutsche Bank AG Invests $1.67 Million in AtriCure, Inc. $ATRC

Key Points

• Deutsche Bank acquired 59,668 AtriCure shares worth approximately $1.67 million in the second quarter, joining several other institutions that initiated or increased positions. Institutional investors collectively own 99.11% of the company.
• AtriCure reported quarterly revenue of $153.6 million, exceeding analyst expectations, and posted earnings of $0.18 per share versus a loss of $0.13 per share a year earlier. The company maintained fiscal 2026 EPS guidance of $0.24 to $0.32.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $49.89, while several firms recently raised their targets to as high as $60. Insiders, however, have sold 53,616 shares worth about $2.15 million over the past 90 days.

Deutsche Bank AG acquired a new position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 59,668 shares of the medical device company's stock, valued at approximately $1,670,000. Deutsche Bank AG owned approximately 0.12% of AtriCure at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Rice Hall James & Associates LLC bought a new position in shares of AtriCure during the second quarter valued at approximately $3,755,000. Global Retirement Partners LLC bought a new position in AtriCure during the 2nd quarter valued at approximately $52,000. Bank of New York Mellon Corp purchased a new position in AtriCure during the second quarter valued at $3,953,000. Handelsbanken Fonder AB raised its stake in AtriCure by 12.3% during the second quarter. Handelsbanken Fonder AB now owns 22,800 shares of the medical device company's stock valued at $638,000 after buying an additional 2,500 shares during the last quarter. Finally, Tactive Advisors LLC bought a new stake in AtriCure in the second quarter worth $374,000. Institutional investors own 99.11% of the company's stock.

AtriCure Stock Performance

ATRC stock opened at $48.54 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. AtriCure, Inc. has a 1 year low of $25.36 and a 1 year high of $49.98. The company has a market cap of $2.47 billion, a P/E ratio of 231.15 and a beta of 1.20. The stock's fifty day moving average price is $37.89 and its 200-day moving average price is $32.26.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The company had revenue of $153.60 million during the quarter, compared to analysts' expectations of $151.80 million. During the same quarter in the prior year, the business earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities analysts forecast that AtriCure, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ATRC has been the subject of several analyst reports. Wall Street Zen downgraded AtriCure from a "strong-buy" rating to a "buy" rating in a report on Saturday, May 2nd. Canaccord Genuity Group raised their price target on shares of AtriCure from $53.00 to $55.00 and gave the company a "buy" rating in a research report on Wednesday, May 6th. Weiss Ratings upgraded shares of AtriCure from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday, August 19th. Piper Sandler upped their price objective on AtriCure from $50.00 to $60.00 and gave the company an "overweight" rating in a research report on Thursday. Finally, BTIG Research increased their target price on AtriCure from $45.00 to $55.00 and gave the company a "buy" rating in a research note on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $49.89.

Insider Transactions at AtriCure

In related news, Director Sven Wehrwein sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total transaction of $946,000.00. Following the completion of the sale, the director directly owned 40,518 shares in the company, valued at approximately $1,533,201.12. The trade was a 38.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Justin J. Noznesky sold 6,182 shares of the company's stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total transaction of $239,861.60. Following the sale, the insider directly owned 100,219 shares of the company's stock, valued at approximately $3,888,497.20. This represents a 5.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 53,616 shares of company stock worth $2,149,994. 4.00% of the stock is currently owned by corporate insiders.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source